| 產(chǎn)品名稱 |
MH-SVM25 [SVM-25] |
| 商品貨號(hào) |
B165154 |
| Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications |
The antibody reacts specifically with HIV-1 gp41. |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Animals were immunized with lysates of purified HIV-1. Spleen cells were fused with NS-1 myeloma cells. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against HTLV-III (HIV-1, human immunodeficiency virus - 1) gp41 (41000 dalton glycoprotein) |
| Cellular Products |
immunoglobulin; monoclonal antibody; against HTLV-III (HIV-1, human immunodeficiency virus - 1) gp41 (41000 dalton glycoprotein) |
| Comments |
Animals were immunized with lysates of purified HIV-1. Spleen cells were fused with NS-1 myeloma cells. The antibody reacts specifically with HIV-1 gp41. |
| Complete Growth Medium |
Dulbecco's modified Eagle's medium with 4.5 g/L glucose, 2 mM L-glutamine, and 1 mM sodium pyruvate, 80%; fetal bovine serum, 20%
|
| Subculturing |
Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Isotype |
IgG1; kappa light chain |
| Name of Depositor |
Akzo Nobel N.V. |
| U.S. Patent Number |
|
| References |
Sarngadharan MG, et al. Monoclonal antibodies for binding HTLV-III proteins, and cell lines for their production. US Patent 4,843,011 dated Jun 27 1989
|
